# Eli Lilly, Novo waging price wars as obesity drug market heats up in China - Seeking Alpha

## Metadata
| Field | Value |
|-------|-------|
| Source | Seeking Alpha |
| URL | https://news.google.com/rss/articles/CBMiggFBVV95cUxQV2RxcWh0ejZCTTNlT0RsNjhDbDV4Q2dnS016cEdGYjlqUzQ4TlVaS2xUZlptYjBlc18tR2VBSV9yNW9Xd0prYzJpcXlSbXNzN05lUF8tTTJsT3lLTThFRWh6SVRLUjdBZEhNVk41c0xWS1FXa3BfUTk2Tm9ZeVdQSUVB?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-30 19:38 |
| Category | GLP-1 |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Eli Lilly and Novo Nordisk are escalating price competition in China's emerging obesity drug market, signaling significant global market expansion and competitive dynamics for GLP-1 treatments.

## Key Entities
Eli Lilly, Novo Nordisk, China

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
